CT-MITSUBISHI-POWER
3.6.2021 20:51:06 CEST | Business Wire | Press release
Mitsubishi Power Aero LLC, a leading provider of global power solutions, and Mitsubishi Power de Mexico, both subsidiaries of Mitsubishi Power Americas, Inc., executed a fast-track, turnkey contract to install and commission five 30-megawatt FT8® MOBILEPAC® aero-derivative, dual-fuel gas turbines for CFEnergia SA de CV (CFEN), a subsidiary of Mexico’s Federal Electricity Commission (CFE). The project, located in Mexicali, Baja California, delivers critical power in time for peak season. A sixth gas turbine will be added later to expand capacity and support next summer’s requirements.
Mitsubishi Power Aero has extensive experience helping customers solve their most urgent power generation needs by providing mobile generation equipment combined with in-house EPC expertise; the FT8 MOBILEPAC gas turbine package is ideally suited for rapid deployment to meet emergency power requirements. The additional power from these units offers peace of mind and energy security to the people and industries in Mexicali. Additionally, as Mexico works toward integrating intermittent renewable energy generation, these gas turbines will play an important role in supplying flexible, reliable, and mobile energy to bolster grid reliability and resilience.
“Although Mexicali has sufficient capacity to meet the region’s power requirements most of the year, there is a shortfall during peak season causing hardship for all who rely on a steady supply of electricity,” said Mitsubishi Power Aero Vice President of Sales and Business Development Harsh Shah. “The mobile generation units that Mitsubishi Power Aero installed will maintain dispatch security, reliability, quality, and continuity in the Baja Electric System. The MOBILEPAC unit’s reliable black start capability affords the ultimate safety net of on-demand power when the need arises.”
Mitsubishi Power Aero President and CEO Raul Pereda noted, “We are pleased that we were able to deliver critical power for CFEnergia on such a tight timeline. The FT8® MOBILEPAC® units are essential assets for Mexico. A compact footprint, minimal site prep, and no permanent foundations give CFE the flexibility to relocate them to other locations to support demand. With the addition of the MOBILEPAC units, CFE operates one of the largest FT8 fleets in the world, an expansion spurred by reliable operational performance and Mitsubishi Power Aero’s strong aftermarket service and support. We deliver power when the world needs it most.”
About Mitsubishi Power Aero LLC
Mitsubishi Power Aero LLC, headquartered in Glastonbury, Connecticut, USA, is a leader in the supply of fast-track, on-demand power solutions to global power producers and industrial and O&G customers. We provide flexible and customizable products and services, including aero-derivative gas turbine packages that generate 30 to 140 MW, tailored and responsive aftermarket services, turnkey EPC expertise, and battery storage. As the demand for electricity expands, and more renewables are added to power grids, Mitsubishi Power Aero will continue to play a vital role in providing energy security to customers around the world. Mitsubishi Power Aero is a group company of Mitsubishi Power Americas, Inc. Connect with us at aero.power.mhi.com and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210603005943/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom